dc.contributor.author |
Sheikh, Hamdullah Khadim |
|
dc.contributor.author |
Tanzila Arshad |
|
dc.contributor.author |
Ghazala Kanwal |
|
dc.date.accessioned |
2023-01-19T04:36:05Z |
|
dc.date.available |
2023-01-19T04:36:05Z |
|
dc.date.issued |
2018-05-16 |
|
dc.identifier.citation |
Sheikh, H. K., Arshad, T., & Kanwal, G. (2018). Aryl sulfonate based anticancer alkylating agents. Pakistan Journal of Pharmaceutical Sciences, 31. |
en_US |
dc.identifier.issn |
1011-601X |
|
dc.identifier.uri |
http://142.54.178.187:9060/xmlui/handle/123456789/16077 |
|
dc.description.abstract |
This research work revolves around synthesis of antineoplastic alkylating sulfonate esters with dual alkylating
sites for crosslinking of the DNA strands. These molecules were evaluated as potential antineoplastic cross linking alkylating agents by reaction with the nucleoside of Guanine DNA nucleobase at both ends of the synthesized molecule. Synthesis of the alkylating molecules and the crosslinking with the guanosine nucleoside was monitored by MALDITOF mass spectroscopy. The synthesized molecule’s crosslinking or adduct forming rate with the nucleoside was compared with that of 1,4 butane disulfonate (busulfan), in form of time taken for the appearance of [M+H]+ . It was found that aryl sulfonate leaving group was causing higher rate of nucleophilic attack by the Lewis basic site of the nucleobase. Furthermore, the rate was also found to be a function of electron withdrawing or donating nature of the substituent on the aryl ring. Compound with strong electron withdrawing substituent on the para position of the ring reacted fastest. Hence, new alkylating agents were synthesized with optimized or desired reactivity. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Karachi: Faculty of Pharmacy & Pharmaceutical Sciences University of Karachi |
en_US |
dc.subject |
Organic synthesis |
en_US |
dc.subject |
alkylation |
en_US |
dc.subject |
MALDI-MS |
en_US |
dc.subject |
antineoplastic |
en_US |
dc.subject |
busulphan |
en_US |
dc.title |
Aryl sulfonate based anticancer alkylating agents |
en_US |
dc.type |
Article |
en_US |